Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
Wegovy semaglutide injection pens. Credit: K KStock/Adobe Stock Two health technology startups have an idea for treating obesity: Use genetic tests and other tests to see whether expensive weight ...
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...
NPA chairman Nick Kaye told the PA news agency that while obesity is "one of the biggest challenges facing" the UK, they are ...
Evening Standard on MSN3d
Pharmacy leaders issue fresh warning over online sales of weight loss jabsPharmacy leaders have issued warnings about the online sale of GLP-1 weight-loss drugs, including Wegovy and Mounjaro ...
Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...
Rybelsus is a GLP-1 agonist with semaglutide, like Ozempic and Wegovy, but it is taken as an oral pill rather than an injection. Who is it for? Rybelsus is approved for adults with type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback